The U.S. Food and Drug Administration (FDA) has released a safety communication warning that the Daytrana patch, used to treat attention deficit hyperactivity disorder (ADHD), can result in permanent loss of skin color.
The Daytrana methylphenidate transdermal system is a prescription patch marketed by Noven Pharmaceuticals for use in treating ADHD. It is supposed to increase attention and decrease distractedness in overactive children and adolescents. The manufacturer directs patients ...
continue reading...